Current management options for latent tuberculosis: a review

References

• World Health OrganizationWorld Health Statistics 2012GenevaWorld Health Organization2012 Available from: http://www.who.int/gho/publications/world_health_statistics/2012/en/index.html. Accessed June 13, 2012.
   Google Scholar
• WeisSEPogodaJMYangZTransmission dynamics of tuberculosis in Tarrant county, TexasAm J Respir Crit Care Med20021661364212091168
   PubMed Web of Science ®Google Scholar
• SmallPMHopewellPCSinghSPThe epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methodsN Eng J Med19943302417031709
   PubMed Web of Science ®Google Scholar
• GoswamiNDGadkowskiLBPiedrahitaCPredictors of latent tuberculosis treatment initiation and completion at a US public health clinic: a prospective cohort studyBMC Public Health201212146822720842
   PubMed Web of Science ®Google Scholar
• SterlingTRVillarinoMEBorisovASTB Trials Consortium PREVENT TB Study TeamThree months of rifapentine and isoniazid for latent tuberculosis infectionN Eng J Med20113652321552166
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Targeted tuberculin testing and treatment of latent tuberculosis infectionMMWR Recomm Rep200049RR–6151
   Google Scholar
• PouchotJGraslandAColletCCosteJEsdaileJMVinceneuxPReliability of tuberculin skin test measurementAnn Intern Med199712632102149027271
   PubMed Web of Science ®Google Scholar
• BakirMMillingtonKASoysalAPrognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contactAnn Intern Med20081491177778718936496
   PubMed Web of Science ®Google Scholar
• DielRLoddenkemperRMeywald-WalterKNiemannSNienhausAPredictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosisAm J Respir Crit Care Med2008177101164117018276940
   PubMed Web of Science ®Google Scholar
• LeungCCYamWCYewWWT-Spot.TB outperforms tuberculin skin test in predicting tuberculosis diseaseAm J Respir Crit. Care Med2010182683484020508217
   PubMed Web of Science ®Google Scholar
• PaiMZwerlingAMenziesDSystematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an updateAnn Intern Med2008149317718418593687
   PubMed Web of Science ®Google Scholar
• MazurekGHJerebJVernonACenters for Disease Control and Prevention (CDC)Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, 2010MMWR Recomm Rep201059RR–512520577159
   PubMedGoogle Scholar
• KippAMStoutJEHamiltonCDVan RieAExtrapulmonary tuberculosis, human immunodeficiency virus, and foreign birth in North Carolina, 1993–2006BMC Public Health2008810718394166
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendationsMMWR Recomm Rep199847RR–20158
   Google Scholar
• TakayamaKWangLDavidHLEffect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of mycobacterium tuberculosisAntimicrob Agents and Chemother19722129354208567
   PubMed Web of Science ®Google Scholar
• WinderFGCollinsPBInhibition by isoniazid of synthesis of mycolic acids in mycobacterium tuberculosisJ Gen Microbiol197063141485500025
   PubMedGoogle Scholar
• HoldinessMRClinical pharmacokinetics of the antituberculosis drugsClin Pharmacokinet1984965115446391781
   PubMed Web of Science ®Google Scholar
• WeberWWHeinDWClinical pharmacokinetics of isoniazidClin Pharmacokinet197946401422391461
   PubMed Web of Science ®Google Scholar
• ComstockGWBaumCSniderDEJrIsoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studiesAm Rev Respir Dis19791195827830453704
   PubMed Web of Science ®Google Scholar
• ComstockGWFerebeeSHHammesLMA controlled trial of community-wide isoniazid prophylaxis in AlaskaAm Rev Respir Dis19679569359436026165
   PubMed Web of Science ®Google Scholar
• Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial International Union Against Tuberculosis Committee on ProphylaxisBull World Health Organ19826045555646754120
   PubMed Web of Science ®Google Scholar
• ComstockGWHow much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?Int J Tuberc Lung Dis199931084785010524579
   PubMed Web of Science ®Google Scholar
• PapeJWJeanSSHoJLHafnerAJohnsonWDJrEffect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infectionLancet199334288662682728101302
   PubMed Web of Science ®Google Scholar
• AkoloCAdetifaIShepperdSVolminkJTreatment of latent tuberculosis infection in HIV infected personsCochrane Database Syst Rev20101CD00017120091503
   PubMed Web of Science ®Google Scholar
• SamandariTAgizewTBNyirendaS6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trialLancet201137797771588159821492926
   PubMed Web of Science ®Google Scholar
• FerebeeSHMountFWTuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contactsAm Review Respir Dis196285490510
   PubMed Web of Science ®Google Scholar
• OckermanPARydeCSerum transaminase levels in pulmonary tuberculosis. Effect of triple treatment with 4-4 1-di-isoamyloxythiocarbanilide or PAS in combination with streptomycin and isoniazidScand J Respir Dis196849135415187250
   PubMedGoogle Scholar
• BerteSJDimaseJDChristiansonCSIsoniazid, para-aminosalicylic acid, and streptomycin intolerance in 1,744 patients. An analysis of reactions to single drugs and drug groups plus data on multiple reactions, type and time of reactions, and desensitizationAm Rev Respir Dis19649059860614221672
   PubMed Web of Science ®Google Scholar
• ScharerLSmithJPSerum transaminase elevations and other hepatic abnormalities in patients receiving isoniazidAnn Intern Med1969716111311205361410
   PubMed Web of Science ®Google Scholar
• MitchellJRZimmermanHJIshakKGIsoniazid liver injury: clinical spectrum, pathology, and probable pathogenesisAnn Intern Med1976842181192766682
   PubMed Web of Science ®Google Scholar
• ByrdRBHornBRSolomonDAGriggsGAToxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patientsJAMA19792411212391241762788
   PubMed Web of Science ®Google Scholar
• KopanoffDESniderDEJrCarasGJIsoniazid-related hepatitis: a US Public Health Service cooperative surveillance studyAm Rev Respir Dis197811769911001666111
   PubMed Web of Science ®Google Scholar
• Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial International Union Against Tuberculosis Committee on ProphylaxisBull World Health Organ19826045555646754120
   PubMed Web of Science ®Google Scholar
• SalpeterSRFatal isoniazid-induced hepatitis. Its risk during chemoprophylaxisWest J Med199315955605648279152
   PubMedGoogle Scholar
• NolanCMGoldbergSVBuskinSEHepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinicJAMA1999281111014101810086436
   PubMed Web of Science ®Google Scholar
• LoBuePAMoserKSUse of isoniazid for latent tuberculosis infection in a public health clinicAm J Respir Crit Care Med2003168444344712746255
   PubMed Web of Science ®Google Scholar
• OestreicherRDresslerSHMiddlebrookGPeripheral neuritis in tuberculous patients treated with isoniazidAm Rev Tuberc195470350450813189066
   PubMedGoogle Scholar
• SniderDEJrPyridoxine supplementation during isoniazid therapyTubercle19806141911966269259
   PubMedGoogle Scholar
• LecoeurHFTruffot-PernotCGrossetJHExperimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamideAm Rev Respir Dis19891405118911932817579
   PubMed Web of Science ®Google Scholar
• A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research CouncilAm Rev Respir Dis1992145136411731596
   PubMed Web of Science ®Google Scholar
• PoleskyAFarberHWGottliebDJRifampin preventive therapy for tuberculosis in Boston’s homelessAm J Respir Crit Care Med19961545147314778912767
   PubMed Web of Science ®Google Scholar
• AsplerALongRTrajmanAImpact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TBThorax201065758258720627913
   PubMed Web of Science ®Google Scholar
• MenziesDDionMJRabinovitchBMannixSBrassardPSchwartzmanKTreatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 monthsAm J Respir Crit Care Med2004170444544915172892
   PubMed Web of Science ®Google Scholar
• YoungHWessolosskyMEllisJKaminskiMDalyJSA retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusettsClin Infect Dis200949342442719548835
   PubMed Web of Science ®Google Scholar
• HollandDPSandersGDHamiltonCDStoutJEStrategies for treating latent multiple-drug resistant tuberculosis: a decision analysisPLoS One201271e3019422272302
   PubMed Web of Science ®Google Scholar
• BlumbergHMBurmanWJChaissonREAmerican Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases SocietyAmerican Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosisAm J Respir Crit Care Med2003167460366212588714
   PubMed Web of Science ®Google Scholar
• LivengoodJrSiglerTGFosterLRBobstJGSniderDEJrIsoniazid-resistant tuberculosis: A community outbreak and report of a rifampin prophylaxis failureJAMA198525319284728493989958
   PubMed Web of Science ®Google Scholar
• MartinsonNABarnesGLMoultonLHNew regimens to prevent tuberculosis in adults with HIV infectionN Eng J Med201136511120
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infectionMMWR Morb Mortal Wkly Rep2002514499899912455909
   PubMedGoogle Scholar
• cdc.gov Managing drug interactions in the treatment of HIV-related tuberculosis Centers for Disease Control and Prevention [updated July 1, 2010]. Available from: http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/RoleofRifamycins.htm. Accessed October 2, 2012.
   Google Scholar
• PageKRSifakisFMontes de OcaRImproved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective studyArch Intern Med2006166171863187017000943
   PubMedGoogle Scholar
• ZiakasPDMylonakisE4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicityClin Infect Dis200949121883188919911936
   PubMed Web of Science ®Google Scholar
• A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: results up to 30 monthsTubercle1975563179189766340
   PubMedGoogle Scholar
• AquinasMAllanWGHorsfallPAAdverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong KongBr Med J1972158037657714259217
   PubMed Web of Science ®Google Scholar
• PooleGStradlingPWorlledgeSPotentially serious side effects of high-dose twice-weekly rifampicinBr Med J1971357703433475314737
   PubMed Web of Science ®Google Scholar
• ZhangYMitchisonDThe curious characteristics of pyrazinamide: a reviewInt J Tuberc Lung Disease20037162112701830
   PubMed Web of Science ®Google Scholar
• GordinFChaissonREMattsJPRifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study GroupJAMA2000283111445145010732934
   PubMed Web of Science ®Google Scholar
• StoutJEEngemannJJChengACFortenberryERHamiltonCDSafety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosisAm J Respir Crit Care Med2003167682482712446275
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection – New York and Georgia, 2000MMWR Morb Mortal Wkly Rep2001501528929111330495
   PubMedGoogle Scholar
• JasmerRMSaukkonenJJBlumbergHMShort-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study InvestigatorsShort-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trialAnn Intern Med2002137864064712379063
   PubMed Web of Science ®Google Scholar
• KeungAEllerMGMcKenzieKAWeirSJSingle and multiple dose pharmacokinetics of rifapentine in man: Part IIInt J Tuberc Lung Disease19993543744410331734
   PubMed Web of Science ®Google Scholar
• JiBTruffot-PernotCLacroixCEffectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in miceAm Rev Respir Dis19931486 Pt 1154115468256897
   PubMed Web of Science ®Google Scholar
• MiyazakiEChaissonREBishaiWRAnalysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosisAntimicrob Agents Chemother19994392126213010471552
   PubMed Web of Science ®Google Scholar
• NuermbergerETyagiSWilliamsKNRosenthalIBishaiWRGrossetJHRifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse modelAm J Respir Crit Care Med2005172111452145616151038
   PubMed Web of Science ®Google Scholar
• ZhangTZhangMRosenthalIMGrossetJHNuermbergerELShort-course therapy with daily rifapentine in a murine model of latent tuberculosis infectionAm J Respir Crit Care Med2009180111151115719729664
   PubMed Web of Science ®Google Scholar
• SchechterMZajdenvergRFalcoGWeekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contactsAm J Respir Crit Care Med2006173892292616474028
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infectionMMWR Morb Mortal Wkly Rep201160481650165322157884
   PubMedGoogle Scholar
• HollandDPSandersGDHamiltonCDStoutJECosts and cost-effectiveness of four treatment regimens for latent tuberculosis infectionAm J Respir Crit Care Med2009179111055106019299495
   PubMed Web of Science ®Google Scholar
• HornDLHewlettDJrAlfallaCPetersonSOpalSMLimited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosisN Engl J Med19943301712418139647
   PubMed Web of Science ®Google Scholar
• LouHXShulloMAMcKaveneyTPLimited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant populationPharmacotherapy200222670170412066961
   PubMed Web of Science ®Google Scholar
• RidzonRMeadorJMaxwellRHigginsKWeismullerPOnoratoIMAsymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacinClin Infect Dis1997246126412659195099
   PubMed Web of Science ®Google Scholar
• YounossianABRochatTKettererJPWackerJJanssensJPHigh hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosisEur Respir J200526346246416135729
   PubMed Web of Science ®Google Scholar
• ComstockGWFrost revisited: the modern epidemiology of tuberculosisAm J Epidemiol197510153633821093397
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Trends in tuberculosis – United States, 2011MMWR Morb Mortal Wkly Rep2012611118118522437911
   PubMedGoogle Scholar
• Centers for Disease Control and PreventionLatent Tuberculosis Infection: A Guide for Primary Health Care Providers Available from: http://www.cdc.gov/tb/publications/ltbi/treatment.htm. Accessed November 13, 2012.
   Google Scholar
• Centers for Disease Control and PreventionLatent Tuberculosis Infection: A Guide for Primary Health Care Providers Available from: http://www.cdc.gov/tb/publications/ltbi/diagnosis.htm. Accessed November 13, 2012.
   Google Scholar